M L Elkjaer1, T Molnar2, Z Illes1,3. 1. Department of Neurology, Odense University Hospital, Odense, Denmark. 2. Department of Anesthesiology and Intensive Care, University of Pecs, Pecs, Hungary. 3. Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Abstract
OBJECTIVES: Teriflunomide 14 mg is a once-daily oral disease-modifying treatment for relapsing-remitting multiple sclerosis. We examined adverse event (AE) profile and efficacy in real life. MATERIALS AND METHODS: In this observational cohort study, we retrospectively examined 1521 blood samples and data of 102 patients followed for up to 28 months. RESULTS: The number of female patients starting teriflunomide peaked in the fifth decade, 10 years later compared to male patients (P<.001), reflecting pregnancy concerns. Seventy-six percentages of patients shifted to teriflunomide from treatment with interferon-beta. Expanded disability status scale improved in 11% of patients (18.2±3.6 months follow-up) and remained constant in 67.5% (15±5.3 months follow-up). Of ten relapses, three occurred within 6 months after starting treatment. Seventeen patients (16.5%) discontinued teriflunomide: 53% because of AEs and 29% because of relapse. Levels of alanine aminotransferase (ALT) remained normal in 95.3% of the blood samples and remained below 1.5 times the upper limit of normal in 91% of the 4.7% abnormal samples. One-third of the patients had abnormal ALT values at least once. Haematological abnormalities were found in <4% of the blood samples, but at least one abnormal value was observed in up to 21% of the patients. CONCLUSIONS: Efficacy and safety of teriflunomide in real-life setting support data obtained by the pivotal trials. Laboratory abnormalities are rare among the large number of samples, but patients may commonly have a single mild, abnormal value if frequently tested.
OBJECTIVES:Teriflunomide 14 mg is a once-daily oral disease-modifying treatment for relapsing-remitting multiple sclerosis. We examined adverse event (AE) profile and efficacy in real life. MATERIALS AND METHODS: In this observational cohort study, we retrospectively examined 1521 blood samples and data of 102 patients followed for up to 28 months. RESULTS: The number of female patients starting teriflunomide peaked in the fifth decade, 10 years later compared to male patients (P<.001), reflecting pregnancy concerns. Seventy-six percentages of patients shifted to teriflunomide from treatment with interferon-beta. Expanded disability status scale improved in 11% of patients (18.2±3.6 months follow-up) and remained constant in 67.5% (15±5.3 months follow-up). Of ten relapses, three occurred within 6 months after starting treatment. Seventeen patients (16.5%) discontinued teriflunomide: 53% because of AEs and 29% because of relapse. Levels of alanine aminotransferase (ALT) remained normal in 95.3% of the blood samples and remained below 1.5 times the upper limit of normal in 91% of the 4.7% abnormal samples. One-third of the patients had abnormal ALT values at least once. Haematological abnormalities were found in <4% of the blood samples, but at least one abnormal value was observed in up to 21% of the patients. CONCLUSIONS: Efficacy and safety of teriflunomide in real-life setting support data obtained by the pivotal trials. Laboratory abnormalities are rare among the large number of samples, but patients may commonly have a single mild, abnormal value if frequently tested.
Authors: Emanuele D'Amico; Aurora Zanghì; Graziella Callari; Giovanna Borriello; Antonio Gallo; Giusi Graziano; Paola Valentino; Maria Buccafusca; Salvatore Cottone; Giuseppe Salemi; Paolo Ragonese; Roberto Bruno Bossio; Renato Docimo; Luigi Maria Edoardo Grimaldi; Carlo Pozzilli; Gioacchino Tedeschi; Mario Zappia; Francesco Patti Journal: Ther Adv Neurol Disord Date: 2018-09-10 Impact factor: 6.570
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Michael Guger; Christian Enzinger; Fritz Leutmezer; Jörg Kraus; Stefan Kalcher; Erich Kvas; Thomas Berger Journal: Acta Neurol Scand Date: 2019-04-22 Impact factor: 3.209
Authors: Michael Guger; Michael Matthias Ackerl; Martin Heine; Christiane Hofinger-Renner; Heinrich Karl Spiss; Andrea Taut; Karin Unger; Fritz Leutmezer Journal: eNeurologicalSci Date: 2022-03-07
Authors: Michael Guger; Christian Enzinger; Fritz Leutmezer; Jörg Kraus; Stefan Kalcher; Erich Kvas; Thomas Berger Journal: J Neurol Date: 2020-04-03 Impact factor: 4.849